Fiona C Brown

9PUBLICATIONS
64CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsGene and molecular therapyMedical parasitology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 15, 2022
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells.

Charis E Teh, Hongke Peng, Meng-Xiao Luo

|Oct 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia.

Donia M Moujalled, Fiona C Brown, Chong Chyn Chua

|Dec 04, 2021
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.

Sylvain Garciaz, Andrew A Guirguis, Sebastian Müller

|Apr 07, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled

|Jul 21, 2020
Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): A Phase Ib Dose-Escalation Study of Venetoclax Combined With Modified Intensive Chemotherapy.

Chong Chyn Chua, Andrew W Roberts, John Reynolds

|Aug 11, 2018
Characterization of Tfrc-mutant mice with microcytic phenotypes.

Ashlee J Conway, Fiona C Brown, Gerhard Rank

Pageof 2